$BHP.AX

If I invest $15,000 in BHP shares, how much passive income will I receive in 2027?

BHP Group Ltd (ASX: BHP) is a popular ASX dividend share with diversified commodity production. In FY26, BHP increased its dividend by 56% to US$1.72 per share, with revenue growth of 15% to US$58.8 billion. Projections suggest a FY27 dividend of US$2.07 per share, yielding 3.4% (4.9% with franking credits). Analysts are mostly neutral, with an average price target of $59.23, implying a slight downside.

Original reporting
Published Sep 19, 2026, 6:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 19, 2026, 7:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
If I invest $15,000 in BHP shares, how much passive income will I receive in 2027? — source image
Decision brief

The 30-second read

$BHP.AXNeutralLow
01

Why it matters

The dividend projection offers a modest income prospect but lacks concrete guidance, limiting trading relevance.

02

Market read

Low trading relevance; primarily an informational piece on dividend expectations.

03

What to watch

Potential capital expenditures on potash project could affect future payouts.

Relevance 4/10Novelty 2/10Timing: none

Background

BHP is a major diversified miner with recent FY26 earnings growth and a projected FY27 dividend.

Company-level read

Ticker impact

$BHP.AXNeutralMedium confidence
Context

Article projects FY27 dividend of $2.07 per share for BHP, a new forecast not previously disclosed.

Expected impact

Limited upside unless dividend expectations shift market sentiment.

Evidence & confidence

Dividend projection is speculative and lacks firm guidance; impact on price likely small.

Market effects

May slightly improve outlook for ASX mining dividend sector.

Limited effect on Australian market; no broader regional impact.

Low relevance to global markets.

Counterpoint

Dividend yield may not compensate for commodity price volatility.

Key entities

  • BHP Group Ltd

    ASX-listed mining conglomerate.

Related articles

$VERAMedAI 8/10

Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results

Vera Therapeutics (VERA) reported strong Phase III results for TRUTAKNA (atacicept) in IgA nephropathy, with mild/moderate adverse events and no serious safety concerns. The drug received accelerated FDA approval in July and is being commercially launched. Vera plans to submit a supplemental biologics license application this quarter, aiming for full approval in mid-2027.

LowAI 8/10

Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne – Thailand Business News

Ascletis Pharma Inc.'s partner, Sagimet Biosciences, has dosed the first patient in a Phase III U.S. trial of denifanstat (ASC40) for moderate to severe acne. The trial aims to enroll 800 patients. Ascletis' prior Phase III trial in China showed ASC40 was more effective than FDA-approved treatments, with 18.6% treatment success vs. 9.4% for sarecycline and 6.7% for doxycycline.